Global Search

Search articles, concepts, and chapters

J GlaucomaJune 20167 citations

Outcomes of Trabeculectomy With Mitomycin-C in Uveitis Associated With Vogt-Koyanagi-Harada Disease.

Almobarak Faisal A, Alharbi Ali H, Morales Jose, Aljadaan Ibrahim


AI Summary

Trabeculectomy with MMC for VKH-associated uveitic glaucoma offers acceptable intermediate-term IOP control, but many eyes require further procedures, highlighting the need for continuous monitoring.

Abstract

Objectives

To evaluate the outcomes of trabeculectomy with mitomycin-C (MMC) in uveitis associated with Vogt-Koyanagi-Harada disease (VKH).

Methods

Retrospective cohort study included 27 eyes of 15 patients with uveitic glaucoma associated with VKH disease who underwent trabeculectomy with MMC as a first glaucoma procedure at King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia between 1992 and 2011. The main outcome measures were: the intraocular pressure (IOP), the number of antiglaucoma medications, the presence of visually threatening complications, and the need for further surgeries to control the IOP.

Results

The mean follow-up was 78.19 months. The IOP decreased significantly from a mean of 40.15±7.0 to 13.12±6.9 mm Hg on the last follow-up (P<0.01) as well as during the whole follow-up period. The number of medications needed to control the IOP also decreased significantly from 3.89±0.6 to 1.04±1.3. The cumulative probabilities of success were 77.8%, 74.1%, 63.0%, and 51.9% at 12, 24, 36, and 48 months postoperatively, respectively. The most common complications were cataract development and progression (53.8%), hypotony (IOP≤5 mm Hg) (33.3%), choroidal effusion (7.4%), and decompressive retinopathy (7.4%). Eight eyes (29.6%) needed a second procedure to control the IOP.

Conclusions

Trabeculectomy with MMC offers an acceptable intermediate term success and IOP control in uveitic glaucoma associated with VKH. However, significant number of eyes needed further procedures to control the pressure. Therefore, continuous monitoring of the pressure is important.


MeSH Terms

AdultAlkylating AgentsCohort StudiesCombined Modality TherapyConjunctivaFemaleGlaucomaHumansIntraocular PressureMaleMitomycinPostoperative ComplicationsRetrospective StudiesTonometry, OcularTrabeculectomyTreatment OutcomeUveitisUveomeningoencephalitic SyndromeYoung Adult

Key Concepts6

Trabeculectomy with mitomycin-C (MMC) in uveitic glaucoma associated with Vogt-Koyanagi-Harada (VKH) disease significantly decreased intraocular pressure (IOP) from a mean of 40.15±7.0 mmHg to 13.12±6.9 mmHg on the last follow-up (P<0.01) over a mean follow-up of 78.19 months.

TreatmentCohortRetrospective Cohort Studyn=27 eyes of 15 patientsCh23Ch41

The number of antiglaucoma medications needed to control IOP in patients with uveitic glaucoma associated with Vogt-Koyanagi-Harada (VKH) disease who underwent trabeculectomy with mitomycin-C (MMC) decreased significantly from 3.89±0.6 to 1.04±1.3.

TreatmentCohortRetrospective Cohort Studyn=27 eyes of 15 patientsCh23Ch29Ch41

The cumulative probabilities of success for trabeculectomy with mitomycin-C (MMC) in uveitic glaucoma associated with Vogt-Koyanagi-Harada (VKH) disease were 77.8% at 12 months, 74.1% at 24 months, 63.0% at 36 months, and 51.9% at 48 months postoperatively.

PrognosisCohortRetrospective Cohort Studyn=27 eyes of 15 patientsCh23Ch41

The most common complications following trabeculectomy with mitomycin-C (MMC) in uveitic glaucoma associated with Vogt-Koyanagi-Harada (VKH) disease were cataract development and progression (53.8%), hypotony (IOP≤5 mmHg) (33.3%), choroidal effusion (7.4%), and decompressive retinopathy (7.4%).

PrognosisCohortRetrospective Cohort Studyn=27 eyes of 15 patientsCh23Ch41

Eight eyes (29.6%) of patients with uveitic glaucoma associated with Vogt-Koyanagi-Harada (VKH) disease who underwent trabeculectomy with mitomycin-C (MMC) needed a second procedure to control the intraocular pressure (IOP).

PrognosisCohortRetrospective Cohort Studyn=27 eyes of 15 patientsCh23Ch41

Trabeculectomy with mitomycin-C (MMC) offers acceptable intermediate-term success and IOP control in uveitic glaucoma associated with Vogt-Koyanagi-Harada (VKH) disease.

TreatmentCohortRetrospective Cohort Studyn=27 eyes of 15 patientsCh23Ch41

Is this article assigned to the wrong chapter(s)? Let us know.